Overview

Overview

Webcast
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers
Wednesday, December 12, 2018 8:00 AM EST
Webcast
Q3 2018 Aptose Biosciences Inc. Earnings Conference Call
Wednesday, November 7, 2018 8:00 AM EST

Corporate Profile

Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.

Latest Investor Information

Stay Connected

Receive Email Alerts
Sign up to receive email alerts whenever Aptose Biosciences, Inc. posts new information to the site. Just click here.

Contact Information

Investor Relations
647-479-9825
ir@aptose.com